Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin A1c values

被引:98
作者
Woerle, HJ [1 ]
Pimenta, WP [1 ]
Meyer, C [1 ]
Gosmanov, NR [1 ]
Szoke, E [1 ]
Szombathy, T [1 ]
Mitrakou, A [1 ]
Gerich, JE [1 ]
机构
[1] Univ Rochester, Sch Med, Dept Med, Rochester, NY 14642 USA
关键词
D O I
10.1001/archinte.164.15.1627
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Increased fasting plasma glucose (FPG) and 2-hour postchallenge plasma glucose (PCPG) levels with normal hemoglobin A(1c) (HbA(1c)) levels are recognized as risk factors for cardiovascular disease. We undertook this study to determine the relationships between FPG and 2-hour PCPG levels over the normal HbA(1c) range and to assess the need to control FPG and 2-hour PCPG levels to achieve HbA(1c) targets recommended by the American Diabetes Association (ADA), International Diabetes Federation (IDF), and American College of Endocrinology (ACE). Methods: The data of all healthy individuals with HbA(1c) values less than 7.0% (N = 457) who underwent oral glucose tolerance tests between 1986 and 2002 for either screening as potential research volunteers (93%) or diagnostic purposes (7%) were analyzed. Results: Of 404 individuals with normal HbA(1c) levels (<6.0%), 60% had normal glucose tolerance, 33% had impaired glucose tolerance, 1% had isolated impaired FPG, and 6% had type 2 diabetes mellitus. Of 161 individuals without normal glucose tolerance, 80% had normal FPG levels. Both FPG and 2-hour PCPG levels increased as HbA(1c) increased and were significantly correlated (r = 0.63, P < .001), but the 2-hour PCPG level increased at a rate 4 times greater than FPG and accounted for a greater proportion of HbA(1c). People who met the IDF and ACE HbA(1c) targets (<6.5%) had significantly lower 2-hour PCPG levels than those who met the ADA target (<7.0%) (P = .03), whereas FPG levels were similar. Conclusions: Most individuals with HbA(1c) values between 6.0% and 7.0% have normal FPG levels but abnormal 2-hour PCPG levels, suggesting that an upper limit of normal for FPG at 110 mg/dL (6.11 mmol/L) is too high and that attempts to lower HbA(1c) in these individuals will require treatment preferentially directed at lowering postprandial glucose levels.
引用
收藏
页码:1627 / 1632
页数:6
相关论文
共 42 条
  • [1] Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
  • [2] 2-S
  • [3] *AM DIAB ASS, 2002, DIABETES CARE S1, V25, pS97, DOI DOI 10.2337/DIACARE.25.2007.S97
  • [4] American Diabetes Association, 2001, Diabetes Care, V24, P775
  • [5] Is there glycemic threshold for mortality risk?
    Balkau, B
    Bertrais, S
    Ducimetiere, P
    Eschwege, E
    [J]. DIABETES CARE, 1999, 22 (05) : 696 - 699
  • [6] Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria
    Barzilay, JI
    Spiekerman, CF
    Wahl, PW
    Kuller, LH
    Cushman, M
    Furberg, CD
    Dobs, A
    Polak, JF
    Savage, PJ
    [J]. LANCET, 1999, 354 (9179) : 622 - 625
  • [7] Glucose tolerance and cardiovascular mortality -: Comparison of fasting and 2-hour diagnostic criteria
    Borch-Johnsen, K
    Neil, A
    Balkau, B
    Larsen, S
    Nissinen, A
    Pekkanen, J
    Tuomilehto, J
    Jousilahti, P
    Lindstrom, J
    Pyörälä, M
    Pyörälä, K
    Eschwege, E
    Gallus, G
    Garancini, MP
    Bouter, LM
    Dekker, JM
    Heine, RJ
    Nijpels, HG
    Stehouwer, CDA
    Feskens, EJM
    Kromhout, D
    Peltonen, M
    Pajak, A
    Eriksson, J
    Qiao, Q
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (03) : 397 - 405
  • [8] What is the real contribution of fasting plasma glucose and postprandial glucose in predicting HbA1c and overall blood glucose control?
    Caputo, S
    Pitocco, D
    Ruotolo, V
    Ghirlanda, G
    [J]. DIABETES CARE, 2001, 24 (11) : 2011 - 2011
  • [9] Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial
    Chiasson, JL
    Josse, RG
    Gomis, R
    Hanefeld, M
    Karasik, A
    Laakso, M
    [J]. LANCET, 2002, 359 (9323) : 2072 - 2077
  • [10] CORBIN R, 2002, ENDOCR PRACT S1, V8, P5